Filtration separation specialist Pall has introduced a new filter
technology that improves the effectiveness of bioburden reduction
in pharmaceutical production and cuts costs.
Invitrogen, a provider of life science technologies, has entered
into new licensing agreements to supply its Gateway Technology and
clones to worldwide genomic research centres. This will allow
scientists and laboratories to share...
Dutch biotech firm Qiagen has announced the acquisition of key
assets of Molecular Staging (MSI), which includes the Whole Genome
Amplification (WGA) technology, designed to eliminate limitations
created by scarce quantities of DNA...
Germany's Boehringer Ingelheim has completed the validation process
for its new biopharmaceutical production plant in Biberach with a
positive inspection by the US Food and Drug Administration (FDA).
Germany's Icon Genetics and Israeli firm Protalix are to
collaborate on a way of hiking protein expression in plant cells to
improve their use a production vehicle for recombinant proteins.
In an unusual move, Finnish science park Medipolis has set up a new
Good Manufacturing Practice (GMP) pilot plant to take advantage of
the growing demand for biopharmaceutical production capacity.
The company Evotec OAI, a drug discovery and development solution
provider to the pharmaceutical and biotechnology industries has
announced the successful expansion of their in vitro and in silico
ADMET (Adsorption, Distribution,...
Germany's Icon Genetics has published details of its proprietary
expression technology, designed to improve the production of
biopharmaceuticals and other proteins in genetically-modified
plants.
The impact on the French chemicals industry of implementing the
European Union's REACH (Registration, Evaluation and Authorisation
of Chemicals) proposals could be as high €800 million in testing
alone and lead to the loss of...
Switzerland's Integra Biosciences has completed a study that
demonstrates how its recently introduced cell culture vessel can
improve the yield of recombinant proteins.
Novartis' generic drugs subsidiary Sandoz has opened two new
manufacturing plants in Austria and Slovenia that mark its entry
into the contract manufacture of biopharmaceuticals using mammalian
cell culture.
The pharmaceutical industry must cut the time its drugs linger in
development and terminate less promising projects earlier if it is
to improve the efficiency and productivity of its R&D
programmes.
The pharmaceutical industry must cut the time its drugs linger in
development and terminate less promising projects earlier if it is
to improve the efficiency and productivity of its R&D
programmes.
